The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Mural Oncology (NASDAQ:MURA – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently ...

Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

Interim analysis findings showed the perioperative treatment group demonstrated a statistically significant improvement in event-free survival compared with adjuvant radiotherapy, with or without ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...